image
Figure 12: Read through agents have shown ‘proof of concept’ for numerous non-communicable diseases [1] - also for communicable viral disease [1]. Amlexanox has demonstrated in vivo proof of concept for management of inflammatory-related obesity and insulin resistance [180].
Goto home»